Across TCGA pan-cancer cohorts, PRG2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PRG2 data layer compared with 19 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher PRG2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRG2 expression acts as an unfavorable survival marker.

LIHC, BLCA, and SKCM are the cancer types where PRG2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.144	0.688	.013	9	view →
BLCA	OS	Median	All	0.197	0.610	.027	6	view →
SKCM	DFS	Median	II,III,IV	0.244	0.684	.007	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: PRG2 tumor-vs-normal RNA expression · all PRG2 data types